RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)

Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj

— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023